China’s Innovative Drug Trading—Transaction Power Trends and Observations!
1. Overview of the Global Innovative Drug BD Market: Chinese innovative drugs are becoming a major force in global transactions. In recent years, the global pharmaceutical
Article
- Welcome to MeritsIP Website -
- Home -Article ( Page 8 )
A clear document clarifies: drug patent compensation period, data protection period, and market exclusivity period
In the work of new drug R&D, registration application, and marketing, three types of drug protection cycles are easily confused: Patent Term Compensation (PTE), Drug Trial
New regulations on centralized drug procurement implemented: If you want to win a bid, first sign an “Intellectual Property Commitment Letter”!
On June 23, the National Joint Drug Procurement Office issued the “12th Batch of National Centralized Volume-Based Drug Procurement Announcement (No. 1),” which introduced several important
First trial ordered to pay 10.3 million yuan! LV sues Jasmine Milk White for trademark infringement!
In early July, a ruling from the Suzhou Intermediate People’s Court in Jiangsu Province thrust a tea beverage brand into the center of public controversy. Tea
Eleven biopharmaceutical companies have completed a new round of financing! (July 7）
Medical technology investment remained active this week! This article reviews Huayuan Zhiyin、Huaxia Yingtai、Gestalt Technology、Progress of financing and product implementation of 12 innovative companies including Ruixin Medical，Covering
Intellectual Property Newsletter by MeritsIP, July 06, 2026
· National Intellectual Property Administration's Party Group Conveys and Implements Xi Jinping's Speech at the 105th Anniversary of the CPC · 2026 Annual Patent Agent Qualification
Overseas BD demand | US CGT pharmaceutical companies searching for late stage assets in hematological oncology/rare diseases
A U.S. cell therapy buyer seeking late-stage assets in the hematologic oncology or rare disease sectors for 2027–2028. 1. Cooperation Requirements The buyer is deeply engaged
Milestone! The world’s first CAR-T therapy for solid tumors has been approved for market launch in China!
On June 22, a major piece of news completely reshaped the global anti-cancer landscape! The National Medical Products Administration has officially approved Shanghai Keji Pharmaceutical’s independently
Selected Summary (Part 2) | Multiple high-quality medical assets showcased, and MeritsIP sincerely invites cooperation and matchmaking!
– Introduction – This article continues to summarize some of the previously publicly disclosed high-quality medical asset projects, covering six major categories of full-track technology platforms:
Selected Summary (Part 1) | Multiple high-quality medical assets showcased, and MeritsIP sincerely invites cooperation and matchmaking!
– Introduction – This article summarizes some of the publicly disclosed high-quality medical asset projects from previous periods, covering six major categories of full-track technology platforms:
